Skip to content

DT-109: The Tripeptide Frontier of Metabolic Health

July 27, 2026 · 23 min

Show notes

This source explores DT-109, an experimental tripeptide that represents a novel approach to treating metabolic and cardiovascular diseases. By analyzing its structure and mechanism, the text highlights how this small molecule distinguishes itself from popular weight-loss drugs by stimulating natural GLP-1 production and directly altering liver metabolism.

All episodes of Today’s discussion

Settings

Display

Language

Decides which stations you see first on the home page.

History

Recently played stations and episodes and your latest searches are only stored in this browser.

Notifications

A short notice when a podcast you follow has a new episode. Turn off single podcasts with the bell on their page.

Account

Save favorites – in the app and on the website.

Keyboard shortcuts

/
Open search
Space
Play or pause
← →
In the player: back 15 s, forward 30 s (episodes) · in a row: next tile
↑ ↓
In a row: target within the tile
Home / End
In a row: first or last tile
Esc
Close window or menu
?
This overview
Now playing

Go to station page

Play next

    Add episodes with “Play next” – they play after the current episode.